Treatment of normal BALB/c splenocytes with anti-mouse IgD antibodies at 0C followed by incubation of the cells at 370C resulted in the formation of soluble factors that selectively inhibit rosette formation of lymphocytes bear- 
We have previously shown that incubation of normal mouse spleen cells with dimeric mouse IgD results in the formation of soluble factors that have affinity for IgD (1) . The factors are derived from Lyt-1 + T cells bearing Fcs receptors (FcR) and could be demonstrated by their ability to inhibit rosette formation of Fc8R+ lymphocytes with IgD-coated fixed ox erythrocytes (E'-IgD). Since the majority of B lymphocytes bear IgD on their surface (2) and a substantial portion of Lyt-1 +, L3T4 + T cells in normal spleen bear Fc8R (1, 3) 
MATERIALS AND METHODS
Immunoglobulins and Antibodies. Monoclonal mouse IgD was obtained from ascitic fluids of BALB/c mice that had been injected.with plasmacytoma TEPC 1017 and was isolated by the method of Finkelman et al. (7) with slight modifications (1) . The purified IgD was in the form of a dimer and contained no other immunoglobulins. Purified mouse IgE from hybridoma H-1-DNP-e-26 (8) and normal rabbit IgG were the same preparations as those previously described (9) . Mouse IgD and IgE were coupled to Sepharose CL-4B; 5-8 mg of protein was coupled to 1 ml of Sepharose.
Specifically purified goat anti-mouse IgD antibodies were kindly supplied by F. D. Finkelman (Uniformed Service University of the Health Sciences, Bethesda, MD). Goat antiserum specific for mouse IgM was purchased from Cappel Laboratories (Cochranville, PA). Anti-pL-chain antibodies in the antisera were purified by using Sepharose that had been immunosorbent coated with IgM from MOPC 104E. Specifically purified anti-mouse immunoglobulin antibodies (polyvalent anti-mouse IgG) were the same preparation as that previously described (10) . The IgG fraction of rabbit antiserum monospecific for mouse IgG1 was described in a previous article (11) . Monoclonal anti-Thy-1 antibody was purchased from New England Nuclear. A rabbit antiserum against mouse brain (anti-brain 9) was described previously (12) . Fluorescein-conjugated goat antimouse immunoglobulin and anti-goat IgG were purchased from Meloy Laboratories (Springfield, VA).
Mouse Spleen Cells and Cell Fractionation. BALB/c mice were purchased from Charles River Breeding Laboratories.
Normal splenic lymphocytes were obtained by passing a spleen cell suspension through a Sephadex G-10 column. T cells in the splenic lymphocytes were depleted by using monoclonal anti-Thy-1 antibody together with rabbit complement (Accurate Chemicals, Westbury, NY) (9) Fractionation of IgD-BF. The factors were purified using mouse IgD-Sepharose by the procedures previously described (1) . Proteins bound to the beads were eluted with 0.1 M glycine hydrochloride (pH 3.0).
The molecular mass of IgD-BF was estimated by gel filtration through a TSK G3000 SWG column (Beckman) that had been calibrated with lactate dehydrogenase, bovine serum albumin, ovalbumin, chymotrypsinogen, and cytochrome c. The procedures were exactly the same as that previously described (1).
Determination of Enhancing Effects of IgD-BF on Secondary PFC Responses. BALB/c mice were immunized by an intravenous injection of 0.2 ml of 1% suspension of SRBC (Baltimore Biological Laboratory). Their spleen cells were obtained 11 'days after priming and were resuspended in RPMI 1640 medium supplemented with 5% fetal calf serum, 15 mM Hepes (pH 7.2), 3 mM L-glutamine, 0.1 mM minimum essential medium (MEM) nonessential amino acids (GIB-CO), 1 x MEM vitamins (GIBCO), 1 mM sodium pyruvate, 50 uM 2-mercaptoethanol, penicillin (100 units/ml), and streptomycin (100 ,ug/ml). Cultures were set up in triplicate in a 96-well culture plate (Corning) in the presence or absence of a sample to be tested. Each well contained 8 x 105 spleen cells and 6 x 105 SRBC in a total volume of 0.2 ml. Unless otherwise described, 20 ,ul of a test sample was added to each well. After culture for 4 days, the number of direct and indirect PFC in the cell suspensions were enumerated by the method of Cunningham and Szenberg (17) . To develop indirect PFC, rabbit anti-mouse IgG1 antibodies were added to a mixture of cultured cells and guinea pig complement. The rabbit antibodies had no inhibitory effect on IgM plaques.
RESULTS
Induction of IgD-BF Formation by Anti-IgD. Normal mouse splenocytes were treated with either anti-IgD or anti-IgM antibodies at 0C for 30 min. After washing, the cells were resuspended in fresh culture medium and incubated overnight at 370C to recover culture filtrates. As shown in Table 1 , culture filtrates of anti-IgD-treated spleen cells inhibited rosette formation of Fc8,R' cells with E'-IgD, whereas the filtrates of anti-IgM-treated cells failed to do so. Fractionation of culture filtrates on IgD-Sepharose indicated that the rosette-inhibiting activity bound to IgD-Sepharose and was recovered by elution at acid pH. It was also found that neither the effluent fraction nor the eluate fraction from IgD-Sepharose (in Table 1 ) inhibited IgE-or IgG-RFC rosettes, indicating that the treatment of normal splenocytes with anti-IgD failed to induce the formation of IgE-BF or IgG-BF.
In order to determine cellular mechanisms for the formation of IgD-BF, each of the populations-unfractionated normal splenocytes, the T-cell-ennched population, the Bcell-enriched population, and the Fc8R+-cell-depleted population-was treated with anti-IgD antibodies at 4TC, and the cells were cultured for 24 hr after washings. As shown in Table 2 , neither the B-cell fraction alone, the T-cell fraction alone, nor the Fc8R+-cell-depleted population formed IgD-BF. However, if the B-cell-enriched population was treated with anti-IgD and the antibody-treated B cells were cultured together with untreated T cells, culture filtrates of the mixed cell populations inhibited IgD-RFC (Table 2) . It was confirmed that the rosette-inhibiting activity in the culture filtrate bound to IgD-Sepharose and was recovered in the acid eluate.
Since the experiments described above suggested that sIgD on B cells is involved in the induction of IgD-BF The percentages of FcAR+ cells in the Fc R+-depleted fraction and unfractionated splenocytes were 3.1% and 20.6%, respectively.
The T-cell-enriched population was L.0o sIg' cells and 88% Thy-1 + cells, whereas the B-cell-enriched population was 91% sIg + cells and 1.6% Thy-1 + cells, as determined by immunofluorescence. The culture filtrates obtained from the cells after anti-IgD treatment was assayed for IgD-BF as described in Table 1 formation, experiments were carried out to determine whether the loss of sIgD on B cells is accompanied by the loss of the ability of anti-IgD-treated cells to induce the factor formation. The B-cell-enniched fraction of normal spleen cells was treated with anti-IgD. Half of the suspension of the antibody-treated cells was kept at 0C for 2 hr, and the remainder was incubated at 3TC for 2 hr.
The latter cell suspension was centrifuged to recover both cell'pellets and supernatants. Cell surface staining of an aliquot of the cells with anti-IgD and fluoresceinated antigoat immunoglobulin antibodies confirmed that sIgD was lost by shedding during the 2-hr incubation of the anti-IgDtreated cells at 370C. Aliquots of normal splenic lymphocytes were then cultured with the antidIgD-treated B cells or supernatant of the antibody-treated B cells incubated at 370C, and IgD-BF in culture filtrates were assessed by rosette inhibition. The results shown in Fig. 1 indicated that the anti-IgD-treated B cells, which were kept at 00C, induced the formation of IgD-BF, whereas the same anti-IgD-treated cells incubated at 370C failed to do so. The results also showed that culture supernatants of the anti-IgD-treated B Proc. Natl. Acad. Sci Table 3 showed that the Fc,8R -cell-depleted population failed to form IgD-BF when they were incubated with the anti-IgD-treated cells. These findings collectively suggested that the interaction of cross-linked sIgD on B cells with Fc,6R on T cells induced the formation of IgD-BF and excluded the possibility that the induction of IgD-BF formation is due to B-cell-derived lymphokine(s).
Enhancement of Secondary Antibody Response by IgD-BF. IgD-BF were obtained by treating normal splenocytes with anti-IgD at 09C, followed by incubation of the cells at 37TC for 24 hr. The factors in culture filtrates were absorbed with IgD-Sepharose and were recovered by elution at acid pH. Since the affinity-purified IgD-BF may contain some lymphokines, the factors were refractionated on IgD-Sepharose. The effluent (unbound) fraction and the acid eluate (bound) fraction from the second IgD-Sepharose were adjusted to 1/10th the volume of the original culture supernatant, and the preparations were assessed for the abilities to affect the in vitro PFC response of SRBC-primed spleen cells. The results shown in Table 4 indicated that the eluate fraction, which contained IgD-BF, enhanced both the IgM-and IgGl-PFC responses, whereas the effluent fraction, which did not contain a detectable amount of IgD)-BF, failed to do so. The possibility was considered that IgD-BF itself might induce the PFC responses of SRBC-primed spleen cells in the absence of antigen. However, when the SRBC-primed spleen cells were cultured with the purified IgD-BF (the eluate fraction from the second IgD-Sepharose column), the numbers of IgM-and IgGl-PFC in the cultures were comparable to those in control cultures, which contained the spleen cells alone (results not shown). In experiments 1 and 2, each fraction was adjusted to 1/10th the volume of the original culture supernatant. In experiment 3, the fraction was 1/20th the volume of the original culture supernatant.
Twenty microliters of the fraction was added to SRBC-primed spleen cell cultures in a total volume of 0.2 ml. IgD-BF was detected by inhibition of rosette formation as described in Table 1 . The numbers represent the percentage of rosette inhibition. The percentage of IgD-RFC detected in the absence of IgD-BF was 24.2 ± 1.0% (mean ± SEM).
To exclude the possibility that the factors responsible for the enhancement of the PFC response nonspecifically bound to Sepharose, another preparation of afflinity-purified IgD-BF was absorbed with IgE-Sepharose, and proteins bound to the beads were eluted at acid pH. Proteins that did not bind to IgE-Sepharose were fractionated again on IgD-Sepharose to obtain the effluent (unbound) and eluate (bound) fractions. As shown in Table 4 Previous studies have shown that IgD-BF induced by IgD dimers consisted of two molecular mass species (1) . Thus, we determined if anti-IgD induced the formation of the two species and which species was responsible for the enhancement of PFC responses. Normal spleen cells were treated with anti-IgD, and the antibody-treated lymphocytes were cultured overnight at 370C. IgD-BF in 30 ml of the culture filtrates were purified by using IgD-Sepharose, and the purified IgD-BF were fractionated on a TSK G3000 column. Distribution of the factors in the eluate fractions was determined by the ability of the fractions to inhibit IgD rosettes. IgD-BF consisted of two molecular mass species of approximately 70 and 34 kDa, as shown in Fig. 2 . The fractions containing IgD-BF were pooled separately, and each pooled fraction was assessed for its ability to enhance the PFC response. The results included in Table 4 The present experiments showed that IgD-BF obtained by stimulation of T cells with polymerized sIgD enhanced both the antigen-induced IgM and IgGl-PFC responses of SRBCprimed spleen cells. The factors present in the affinitypurified IgD-BF that are responsible for the enhancement of antibody responses failed to bind to IgE-Sepharose but bound to IgD-Sepharose and were recovered from IgDSepharose by elution at acid pH. It was also found that IgD-BF in the affinity-purified preparation consisted of two molecular mass species of 70 and 34 kDa and that both species enhanced the IgM-and IgGl-PFC responses. In our previous publication (1), it was found that Lyt-1+ T cells treated with dimeric IgD formed the 78-and 37-kDa IgD-BF, Elution Volume (ml) (19) . Finkelman et al. (20) reported that an intravenous injection of goat anti-IgD antibodies into mice induces the formation of interleukih 4 by their spleen cells. As the polyclonal immunoglobulin production by the anti-IgD treatment requires T cells, they interpreted that the goat antibodies were recognized as a foreign antigen for the polyclonal activation of B cells (20) . Nevertheless, an injection of the monoclonal mouse antibody specific for IgD of the a allotype significantly enhanced both IgG1 and IgE production (21 
